Reply

Clin Gastroenterol Hepatol. 2018 Apr;16(4):598-599. doi: 10.1016/j.cgh.2017.12.030.

Authors

Konstantinos Papamichael¹, Adam S Cheifetz¹, Mark T Osterman²

Affiliations

¹ Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
² Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

PMID: 29555231
DOI: 10.1016/j.cgh.2017.12.030

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Inflammatory Bowel Diseases*
Infliximab

Substances

Infliximab